Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Stroke-related cardiac death is a significant concern for patients with stroke and their healthcare providers. It is a complex and multifaceted condition that requires careful management of both modifiable and non-modifiable risk factors. This review provides an overview of the pathophysiology, risk factors, and prevention strategies for stroke-related cardiac death. The review highlights the importance of identifying and managing modifiable risk factors such as hypertension, diabetes, and lifestyle factors, as well as non-modifiable risk factors such as age and genetics. Additionally, the review explores emerging strategies for prevention, including the use of wearable devices and genetic testing to identify patients at risk, stem cell therapy and gene therapy for cardiac dysfunction, and precision medicine for personalized treatment plans. Despite some limitations to this review, it provides valuable insights into the current understanding of stroke-related cardiac death and identifies important areas for future research. Ultimately, the implementation of evidence-based prevention strategies and personalized treatment plans has the potential to improve outcomes for patients with stroke and reduce the burden of stroke-related cardiac death in the population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284691 | PMC |
| http://dx.doi.org/10.2174/011573403X259676231222053709 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism of Stroke Related to a Small Peridevice Leak Coupled with "Reverse" Device-Related Thrombus.
JACC Clin Electrophysiol
August 2025
TriHealth Heart & Vascular Institute, Bethesda North Hospital, Cincinnati, Ohio, USA. Electronic address:
What stroke survivors say about living with upper limb spasticity and how they manage it.
Aust Occup Ther J
October 2025
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Introduction: Post-stroke spasticity can cause serious impairment, activity limitation, and participation restrictions for survivors, leading to stroke-related disability. While there are hundreds of qualitative studies regarding stroke survivor experience, the phenomenon of what it is like to have post-stroke spasticity is not well understood.
Methods: Ten community-dwelling adults with chronic stroke and upper limb spasticity who had recently participated in an intensive upper limb rehabilitation programme were interviewed.
Background: Ischemic stroke results in significant morbidity and mortality. By examining gene expression of cells comprising stroke clots, we aim to gain valuable insights into the underlying mechanisms of this disease and identify potential biomarkers of stroke cause.
Methods: We employed single-cell RNA sequencing to analyze 10 clot samples from patients diagnosed with large vessel occlusion stroke.
Should We Stop Endovascular Treatment of M2 Occlusions?: A Critical Look at Recent Evidence.
Stroke
September 2025
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY (A.M., D.G., J.F., J.M.).
Medium vessel occlusions represent a substantial proportion of patients with acute ischemic stroke. Recently presented randomized controlled trials, ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions), DISTAL (Endovascular Therapy Plus Best Medical Treatment [BMT] Versus BMT Alone for Medium Distal Vessel Occlusion Stroke), and DISCOUNT (Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion), did not demonstrate a clinical benefit of endovascular thrombectomy in distal and medium vessel occlusions, potentially generating uncertainty about optimal treatment strategies for medium vessel occlusions. Specifically, these results may lead clinicians to hesitate in performing endovascular thrombectomy for M2 occlusions, despite prior evidence indicating benefit in this subgroup.
View Article and Find Full Text PDFStroke-related mortality trends among tobacco users in the U.S.: A 21-year retrospective analysis of national data from the CDC WONDER database.
J Stroke Cerebrovasc Dis
October 2025
Department of Neurology, Marshall University, Huntington, WV, USA. Electronic address:
Introduction: Stroke is a leading cause of mortality, and tobacco use is a significant modifiable risk factor. This study analyzed trends in tobacco-associated stroke mortality in the United States from 1999 through 2023 using CDC WONDER data.
Methods: We included adults aged ≥ 25 years with cerebrovascular disease (ICD-10 I60-I69) as the underlying cause of death and tobacco-related disorders (ICD-10 F17.